AstraZeneca plc Rating Reiterated by Barclays (AZN)
AstraZeneca plc (LON:AZN)‘s stock had its “equal weight” rating reiterated by equities researchers at Barclays in a research report issued on Friday, American Banking News.com reports.
AZN has been the subject of a number of other recent research reports. Analysts at Bryan Garnier & Cie reiterated a “neutral” rating on shares of AstraZeneca plc in a research note on Wednesday. They now have a GBX 3,830 ($64.33) price target on the stock. Separately, analysts at UBS AG reiterated a “buy” rating on shares of AstraZeneca plc in a research note on Wednesday. They now have a GBX 4,600 ($77.26) price target on the stock. Finally, analysts at Citigroup Inc. upgraded shares of AstraZeneca plc to a “buy” rating in a research note on Wednesday. They now have a GBX 4,900 ($82.30) price target on the stock, up previously from GBX 3,500 ($58.78). Nine investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of GBX 3,725.76 ($62.58).
AstraZeneca plc (LON:AZN) traded down 2.28% during mid-day trading on Friday, hitting GBX 4080.00. The stock had a trading volume of 3,697,668 shares. AstraZeneca plc has a one year low of GBX 3028.50 and a one year high of GBX 4147.0728. The stock has a 50-day moving average of GBX 3911. and a 200-day moving average of GBX 3670.. The company’s market cap is £51.293 billion.
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.